Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Benzinga Newsdesk www.benzinga.com Neutral 55.9%

Neg 0% Neu 55.9% Pos 0%

Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.